☆ 4.6 Review

Invasive Fungal Infections Associated with COVID-19

JOURNAL OF FUNGI (2023)

Related references

Note: Only part of the references are listed.

Article Ecology

Comparative Host-Pathogen Interaction Analyses of SARS-CoV2 and Aspergillus fumigatus, and Pathogenesis of COVID-19-Associated Aspergillosis

Abdul Arif Khan et al.

Summary: COVID-19 has caused a global catastrophe, with an increased occurrence of invasive pulmonary aspergillosis infection in patients, even in the absence of traditional risk factors. Further research is needed to explore the mechanism between SARS-CoV2 and aspergillosis in order to better address these diseases.

MICROBIAL ECOLOGY (2022)

Add to Collection

Article Microbiology

A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-Resistant Candida parapsilosis in the COVID-19 Era

Danilo Y. Thomaz et al.

Summary: This study investigated an inter-hospital candidemia outbreak caused by fluconazole-resistant Candida parapsilosis (FRCP) during the first year of the COVID-19 pandemic in Brazil. The results showed that the majority of FRCP isolates from a cardiology center, which shared ICU patients with a cancer center, had the same genetic profile and mutation as the strain responsible for the ongoing outbreak in the cancer center, indicating the continuous horizontal transmission of clonal isolates in hospitals during the COVID-19 pandemic.

JOURNAL OF FUNGI (2022)

Add to Collection

Review Infectious Diseases

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries

Martin Hoenigl et al.

Summary: Reports of COVID-19-associated mucormycosis, particularly among patients with uncontrolled diabetes, have been increasing since early 2021. Most patients with COVID-19-associated mucormycosis have uncontrolled diabetes and receive systemic corticosteroid treatment, and rhino-orbital cerebral mucormycosis is the most common disease. COVID-19-associated mucormycosis is associated with high mortality and a significant proportion of survivors experience life-changing morbidities.

LANCET MICROBE (2022)

Add to Collection

Article Dermatology

Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India

Ameet Dravid et al.

Summary: This study investigated the cases of COVID-19 associated mucormycosis (CAM) in India and found that diabetes and steroid use were associated with increased risk of death. A combination of surgical debridement and antifungal therapy showed improvement in the majority of cases.

MYCOSES (2022)

Add to Collection

Article Microbiology

Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis

Antonio Ramos-Martinez et al.

Summary: Severely ill COVID-19 patients have a high risk of acquiring infections in the hospital, and the incidence of candidemia increased significantly during the pandemic period. Candidemia due to fluconazole-resistant C. parapsilosis (FRCP) was more common in patients admitted for COVID-19.

JOURNAL OF FUNGI (2022)

Add to Collection

Review Microbiology

Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions

Matthias Egger et al.

Summary: Cases of COVID-19-associated pulmonary aspergillosis (CAPA) were reported early in the pandemic, but it remains challenging to diagnose. The clinical and radiological manifestations of CAPA are similar to severe COVID-19, so mycological evidence is crucial for diagnosis. However, blood tests lack sensitivity in early stages and mortality rates are high even with antifungal therapy. Testing bronchoalveolar lavage (BAL) is essential for accurate diagnosis.

JOURNAL OF FUNGI (2022)

Add to Collection

Article Endocrinology & Metabolism

COVID-19-associated Mucormycosis: A clinico-epidemiological study

Jaya Chakravarty et al.

Summary: There was a significant increase in COVID-19-associated mucormycosis (CAM) cases during the second wave of the pandemic in India. Uncontrolled hyperglycemia, SARS-CoV-2 infection, widespread use of antibiotics, zinc supplementation, and steroids were identified as risk factors for mucormycosis. Despite the large number of patients, the six-month mortality rate was lower than expected.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2022)

Add to Collection

Review Immunology

COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic

Pankaj Chandley et al.

Summary: Mucormycosis is an invasive fungal infection caused by fungi belonging to order Mucorales. With the increase in COVID-19 infections, mucormycosis has become a global concern due to its high morbidity and mortality rates. This review focuses on the incidence, pathophysiology, diagnostic procedures, treatment options, and future developments of COVID-19-associated mucormycosis.

VACCINES (2022)

Add to Collection

Article Infectious Diseases

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era

Christina Routsi et al.

Summary: This study aimed to investigate the incidence of candidemia, Candida species distribution, and fluconazole resistance among ICU patients during the COVID-19 pandemic. The results showed a significant increase in the incidence of candidemia, non-albicans Candida species, and fluconazole resistance in ICU patients with COVID-19 compared to pre-pandemic periods. ICU length of stay and the presence of shock were associated with different Candida species and fluconazole susceptibility.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Immunology

Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study

Michele Bartoletti et al.

Summary: The study showed a high incidence of CAPA among critically ill COVID-19 patients, and its occurrence seems to alter the natural course of the disease.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Endocrinology & Metabolism

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Awadhesh Kumar Singh et al.

Summary: This systematic review analyzed the characteristics of patients with both COVID-19 and mucormycosis, finding a high proportion of cases in males, 80% with pre-existing diabetes, and a significant use of corticosteroids in treating COVID-19, contributing to mortality in some cases.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

Add to Collection

Article Microbiology

COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory

Andrew M. Borman et al.

Summary: Diagnosing CAPA poses challenges due to the lack of standardized algorithms and definitions, reluctance among clinicians to perform aerosol-generating bronchoalveolar lavages for testing, and uncertainty surrounding the diagnostic sensitivity of serum biomarkers. The study highlights the importance of a multimodal diagnostic approach involving regular and repeat testing of both serum and respiratory samples when diagnosing CAPA.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Candidemia in COVID-19 treated with corticosteroids and tocilizumab

Koichiro Yamamoto et al.

Summary: COVID-19 patients treated with anti-inflammatory drugs rarely develop candidemia, but clinicians should actively monitor for latent candidemia during severe COVID-19 treatment.

CLINICAL CASE REPORTS (2021)

Add to Collection

Review Immunology

COVID-19 associated with pulmonary aspergillosis: A literature review

Chih-Cheng Lai et al.

Summary: Co-infections of Aspergillus spp. in patients with COVID-19, especially in severe/critical cases, have been reported with incidence ranging from 19.6% to 33.3%. Acute respiratory distress syndrome and high mortality rates are common complications, while early diagnosis through fungus culture and galactomannan testing is crucial for appropriate management. Vigilance and aggressive microbiological studies are recommended for severe/critical COVID-19 patients to detect pulmonary aspergillosis promptly.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2021)

Add to Collection

Article Infectious Diseases

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort

Sarah Delliere et al.

Summary: Invasive pulmonary aspergillosis (IPA) is a relatively common complication in severe COVID-19 patients, leading to increased mortality. Treatment with azithromycin for >= 3 days is associated with higher risk of developing probable IPA, while high-dose dexamethasone may also play a role in IPA occurrence.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Dermatology

Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic

Marcio Nucci et al.

Summary: The incidence of candidemia in our hospital had been stable for 18 years at 1.3 episodes per 1000 admissions, but since March 2020, there has been an increase in cases. This increase may be attributed to a reduction in admissions and the occurrence of candidemia in COVID-19 patients.

MYCOSES (2021)

Add to Collection

Article Medicine, General & Internal

Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021

Abby P. Douglas et al.

Summary: Invasive aspergillosis poses significant challenges in haematology/oncology patients, with high mortality rates and potential resistance to antifungal treatment. Diagnosis still relies on culture and histological methods, but non-culture methods are increasingly recognized for their utility. Voriconazole remains the preferred first-line antifungal agent, with recommendations for switching to different antifungal classes for refractory cases.

INTERNAL MEDICINE JOURNAL (2021)

Add to Collection

Correction Infectious Diseases

Clinical characteristics and risk factors for COVID-19-associated Candidemia (vol 59, pg 1262, 2021)

Ali S. Omrani et al.

MEDICAL MYCOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Notes from the Field: COVID-19–Associated Mucormycosis — Arkansas, July–September 2021

Theresa M. Dulski et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Systematic Review Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review

W. H. Chong et al.

Summary: CAPA is defined as invasive pulmonary aspergillosis occurring in COVID-19 patients, with a high mortality rate of 48.4%. The diagnosis is limited by lack of standardized criteria, necessitating further research to determine the optimal diagnostic approach.

JOURNAL OF HOSPITAL INFECTION (2021)

Add to Collection

Review Dermatology

Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis

Hayato Mitaka et al.

Summary: The study aimed to determine the incidence and mortality of COVID-19-associated pulmonary aspergillosis in critically ill patients through systematic review and meta-analysis. The estimated incidence and mortality rates of CAPA in the ICU were 10.2% and 54.9%, respectively. Prospective cohort studies are needed to validate these findings and improve surveillance and prognostication in the ICU.

MYCOSES (2021)

Add to Collection

Review Mycology

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

Valliappan Muthu et al.

Summary: The COVID-19 pandemic has led to a concerning resurgence of mucormycosis, with a high number of cases reported from India. Diabetes mellitus was the most common underlying risk factor for COVID-19-associated mucormycosis in India, where the fatality rate of reported cases was relatively lower compared to globally reported cases.

MYCOPATHOLOGIA (2021)

Add to Collection

Article Dermatology

ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries

Shivaprakash M. Rudramurthy et al.

Summary: Globally, the incidence of COVID-19-associated mucormycosis (CAM) is rising, with a significant surge in India. The need to address misconceptions in managing and treating this infection is crucial, with a focus on early suspicion, diagnosis confirmation, glycemic control, surgical debridement, and antifungal therapy. Limited availability of amphotericin B formulations during the epidemic has led to discussions on alternative antifungal therapies.

MYCOSES (2021)

Add to Collection

Review Critical Care Medicine

Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements

G. Montrucchio et al.

Summary: The review identified 21 English-language articles published before 2020, focusing on risk factors for COVID-19-associated pulmonary aspergillosis (CAPA), including host comorbidities, ICU management, and COVID-19 therapies. The results suggest that previous host risk factors, especially respiratory diseases, still play a crucial role; however, the attention is shifting from individual patient-related risk factors to factors characterizing hospital and ICU processes influenced by COVID treatment.

ANNALS OF INTENSIVE CARE (2021)

Add to Collection

Article Immunology

A High Frequency of Candida auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study

Ekadashi Rajni et al.

Summary: The study assessed the incidence and risk factors for candidemia in COVID-19 patients admitted to ICUs in India, revealing an increased incidence in COVID-19 patients, with tocilizumab use, ICU stay duration, and elevated ferritin level as independent predictors for candidemia development.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1

Nico A. F. Janssen et al.

Summary: An observational study found an incidence of 10%-15% of coronavirus-disease associated pulmonary aspergillosis in intensive care units, with several factors independently associated with the disease in one cohort and mortality rates ranging from 43%-52%.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls

Andrea Mastrangelo et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India

Atul Patel et al.

Summary: This study found an increase in mucormycosis cases in India during the COVID-19 pandemic, mainly due to inappropriate glucocorticoid use, resulting in a higher mortality rate among mucormycosis patients.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Review Environmental Sciences

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

Salman Hussain et al.

Summary: This study found a high incidence of CAM with a high mortality rate among COVID-19 patients. The most common symptoms observed in CAM patients include facial pain, ptosis, and proptosis. Patients who underwent both medical and surgical management had a higher survival rate.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Article Critical Care Medicine

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Matthieu Schmidt et al.

Summary: Among more than 4000 critically ill patients with COVID-19 admitted to our ICUs, 90-day mortality was 31% and decreased from 42 to 25% over the study period. Mortality was higher in older, diabetic, obese and severe ARDS patients.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Letter Immunology

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

Spinello Antinori et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Letter Critical Care Medicine

COVID-19-associated invasive pulmonary aspergillosis

Lynn Rutsaert et al.

ANNALS OF INTENSIVE CARE (2020)

Add to Collection

Article Medicine, General & Internal

Bloodstream infections in critically ill patients with COVID-19

Daniele Roberto Giacobbe et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Editorial Material Respiratory System

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Darius Armstrong-James et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Letter Mycology

Critically ill patients with COVID-19 and candidaemia: We must keep this in mind

A. Agrifoglio et al.

JOURNAL DE MYCOLOGIE MEDICALE (2020)

Add to Collection

Review Microbiology

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment

Amir Arastehfar et al.

JOURNAL OF FUNGI (2020)

Add to Collection

Review Microbiology

COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges

Aia Mohamed et al.

JOURNAL OF FUNGI (2020)

Add to Collection

Article Endocrinology & Metabolism

Hyperglycemia and COVID-19: What was known and what is really new?

Antonio Ceriello

DIABETES RESEARCH AND CLINICAL PRACTICE (2020)

Add to Collection

Article Critical Care Medicine

Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series

Antine W. Flikweert et al.

JOURNAL OF CRITICAL CARE (2020)

Add to Collection

Review Microbiology

COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?

Amir Arastehfar et al.

JOURNAL OF FUNGI (2020)

Add to Collection

Review Infectious Diseases

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Philipp Koehler et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020

Anuradha Chowdhary et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, Research & Experimental

A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient

Kathy Hoang et al.

MEDICAL MYCOLOGY CASE REPORTS (2020)

Add to Collection

Review Infectious Diseases

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Oliver A. Cornely et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Review Microbiology

Global Epidemiology of Mucormycosis

Hariprasath Prakash et al.

JOURNAL OF FUNGI (2019)

Add to Collection

Article Infectious Diseases

Secular trends of candidemia at a Brazilian tertiary care teaching hospital

Paula Rocha Braga et al.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Review Endocrinology & Metabolism

Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review

Hector Eloy Tamez-Perez et al.

WORLD JOURNAL OF DIABETES (2015)

Add to Collection

Article Immunology

Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have zygomycosis

Georgios Chamilos et al.

CLINICAL INFECTIOUS DISEASES (2008)

Add to Collection

Review Immunology

Epidemiology and outcome of zygomycosis: A review of 929 reported cases

MM Roden et al.

CLINICAL INFECTIOUS DISEASES (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.